# Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

> **NCT06394973** · PHASE2 · COMPLETED · sponsor: **Laboratoires Thea** · enrollment: 161 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** T4090 0.2%
- **DRUG:** T4090 0.3%
- **DRUG:** Rhopressa®

## Key facts

- **NCT ID:** NCT06394973
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-05
- **Primary completion:** 2024-11-21
- **Final completion:** 2024-11-21
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06394973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06394973, "Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06394973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*